How melanoma and other tumors succeed in hiding and resisting immunotherapy

Cutaneous melanoma, the most aggressive form of skin cancer, is characterized by its accumulation of a large number of mutations. Although some of these alterations should be recognized as a threat by our defenses, melanomas often escape immune system surveillance. As a result, more than half of patients do not generally respond to current immunotherapies. Understanding and avoiding this phenomenon is one of the greatest challenges in oncology today.